Altimmune (NASDAQ:ALT) Trading Up 10.7% – Should You Buy?

Altimmune, Inc. (NASDAQ:ALT)’s stock price was up 10.7% on Tuesday . The stock traded as high as $7.13 and last traded at $7.12. Approximately 1,715,799 shares changed hands during mid-day trading, a decline of 56% from the average daily volume of 3,911,374 shares. The stock had previously closed at $6.43.

Analyst Ratings Changes

Several research analysts have commented on the stock. B. Riley restated a “buy” rating and issued a $20.00 target price on shares of Altimmune in a research report on Monday, August 12th. HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Altimmune in a report on Thursday, August 22nd. Evercore ISI raised Altimmune to a “strong-buy” rating in a research note on Friday, August 9th. Finally, Piper Sandler reissued an “overweight” rating and issued a $25.00 price target on shares of Altimmune in a research note on Friday, June 21st. Two investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $18.80.

Altimmune Price Performance

The firm has a fifty day moving average price of $6.65 and a 200 day moving average price of $7.02. The firm has a market capitalization of $499.15 million, a PE ratio of -4.35 and a beta of 0.08.

Altimmune (NASDAQ:ALT) last released its earnings results on Thursday, August 8th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.01). The firm had revenue of $0.01 million during the quarter. Altimmune had a negative return on equity of 53.09% and a negative net margin of 24,778.97%. During the same quarter in the prior year, the business posted ($0.32) earnings per share. On average, sell-side analysts expect that Altimmune, Inc. will post -0.54 EPS for the current year.

Insider Buying and Selling at Altimmune

In other Altimmune news, Director David Drutz sold 16,011 shares of Altimmune stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $6.90, for a total transaction of $110,475.90. Following the transaction, the director now owns 41,958 shares of the company’s stock, valued at $289,510.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On Altimmune

Institutional investors have recently modified their holdings of the stock. North Star Investment Management Corp. acquired a new stake in shares of Altimmune during the 1st quarter valued at about $31,000. CANADA LIFE ASSURANCE Co acquired a new stake in Altimmune in the first quarter valued at approximately $44,000. TFO Wealth Partners LLC bought a new stake in Altimmune in the first quarter worth approximately $51,000. Horizon Wealth Management LLC acquired a new position in shares of Altimmune during the 2nd quarter worth $66,000. Finally, PFG Investments LLC bought a new position in shares of Altimmune during the 2nd quarter valued at $67,000. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.